ADPT Adaptive Biotechnologies Corp
FY2025 10-K
Adaptive Biotechnologies Corp (ADPT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of immune medicine products using proprietary sequencing to decode adaptive immune system for diagnostics and therapeutics
- • New focus in 2024: Reorganization into MRD business specializing in clonoSEQ testing and Immune Medicine (IM) business emphasizing immune receptor sequencing and TCR-antigen mapping
Management Discussion & Analysis
- • Revenue $277.0M in 2025, up 55% YoY from $179.0M in 2024; MRD revenue $212.3M (+46%) and Immune Medicine $64.6M (+93%)
- • Operating margin negative: loss from operations $(57.1)M in 2025 vs $(162.5)M in 2024; Adjusted EBITDA positive $12.2M in 2025 vs loss $(80.4)M prior
Risk Factors
- • Regulatory risk: Potential non-coverage or inadequate reimbursement for clonoSEQ diagnostic tests by private and government payors affecting revenue
- • Geopolitical/macroeconomic risk: Dependence on Illumina as sole supplier for sequencers and reagents, risking operational disruption if supply is interrupted
Financial SummaryXBRL
Revenue
$277M
Net Income
-$59M
Operating Margin
-20.6%
Net Margin
-21.5%
ROE
-27.2%
Total Assets
$513M
EPS (Diluted)
$-0.39
Operating Cash Flow
-$46M
Source: XBRL data from Adaptive Biotechnologies Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Adaptive Biotechnologies Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.